Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Center For Cancer Research & Therapeutic Development Clark Atlanta University currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's prosecution is highly concentrated, with only 1 distinct examiner and 1 distinct art unit involved in the current workload. This suggests a focused research and development effort that falls within a specific technical domain at the patent office.
The busiest examiner for this entity is SULLIVAN, STEPHANIE LAUREN, who is handling 1 busiest examiner pending office action. This 1 action represents the entirety of the pending prosecution for the center, making the examiner's specific feedback the primary focus for the legal team. With only 1 distinct art unit involved, the prosecution environment is consistent and lacks the complexity of dealing with multiple administrative groups.
The practitioner's strategy should be tailored to the 1 pending office action and the specific requirements of SULLIVAN, STEPHANIE LAUREN. Reviewing the examiner's past decisions in the Biotechnology & Pharmaceuticals area can help in preparing a more effective response. Successfully navigating the 1 pending office action with this 1 examiner is essential for advancing the center's intellectual property goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.1% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17293003 | IDENTIFICATION OF JUND TARGET GENES FOR INHIBITION OF PROSTATE CANCER CELL GROWTH | SULLIVAN, STEPHANIE LAUREN | 69d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17293003 | IDENTIFICATION OF JUND TARGET GENES FOR INHIBITION OF PROSTATE CANCER CELL GROWTH | SULLIVAN, STEPHANIE LAUREN | 69d |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17293003 | IDENTIFICATION OF JUND TARGET GENES FOR INHIBITION OF PROSTATE CANCER CELL GROWTH | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§112 | Non-Final OA | 69d | Pending | May 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial